Effects of JDTic, a selective kappa-opioid receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model.

[1]  R. Spanagel,et al.  Endogenous κ-opioid systems in opiate withdrawal: role in aversion and accompanying changes in mesolimbic dopamine release , 1994, Psychopharmacology.

[2]  James L. Howard,et al.  Pharmacological properties of JDTic: a novel κ-opioid receptor antagonist , 2004 .

[3]  K. Befort,et al.  Mu opioid receptor: a gateway to drug addiction , 2004, Current Opinion in Neurobiology.

[4]  James B. Thomas,et al.  Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. , 2003, Journal of medicinal chemistry.

[5]  Philip S. Portoghese,et al.  Antidepressant-Like Effects of κ-Opioid Receptor Antagonists in the Forced Swim Test in Rats , 2003, Journal of Pharmacology and Experimental Therapeutics.

[6]  E. Butelman,et al.  Pharmacotherapy of addictions , 2002, Nature Reviews Drug Discovery.

[7]  C. Gaveriaux-Ruff,et al.  Opioid receptor genes inactivated in mice: the highlights , 2002, Neuropeptides.

[8]  Jisheng Han,et al.  Spinal kappa-opioid system plays an important role in suppressing morphine withdrawal syndrome in the rat , 2000, Neuroscience Letters.

[9]  M. Aceto,et al.  Dihydroetorphine: physical dependence and stereotypy after continuous infusion in the rat. , 2000, European journal of pharmacology.

[10]  B. H. Hill,et al.  An open-label study of a functional opioid κ antagonist in the treatment of opioid dependence , 2000 .

[11]  B. Kieffer.  Opioids: first lessons from knockout mice. , 1999, Trends in pharmacological sciences.

[12]  B. Roques,et al.  Disruption of the κ‐opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective κ‐agonist U‐50,488H and attenuates morphine withdrawal , 1998, The EMBO journal.

[13]  G. Koob,et al.  Precipitation of morphine withdrawal syndrome in rats by administration of mu-, delta- and kappa-selective opioid antagonists , 1992, Neuropharmacology.

[14]  H. Akil,et al.  Regulation of striatonigral prodynorphin peptides by dopaminergic agents , 1990, Brain Research.

[15]  G. Hanson,et al.  Effects of cocaine on extrapyramidal and limbic dynorphin systems. , 1990, The Journal of pharmacology and experimental therapeutics.

[16]  S. Sivam.  Cocaine selectively increases striatonigral dynorphin levels by a dopaminergic mechanism. , 1989, The Journal of pharmacology and experimental therapeutics.

[17]  H. Akil,et al.  Changes in prodynorphin peptide content following treatment with morphine or amphetamine: possible role in mechanisms of action of drug of abuse. , 1989, NIDA research monograph.

[18]  C. Haertzen,et al.  Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. , 1986, The Journal of pharmacology and experimental therapeutics.

[19]  H. Emrich,et al.  Psychotomimesis mediated by kappa opiate receptors , 1986, Science.

[20]  D. Teiger.  Induction of physical dependence on morphine, codeine and meperidine in the rat by continuous infusion. , 1974, The Journal of pharmacology and experimental therapeutics.

[21]  L. Magos.  Persistence of the effect of amphetamine on stereotyped activity in rats. , 1969, European Journal of Pharmacology.